ZSAN Zosano Pharma Corp

Zosano Pharma Reports Second Quarter 2021 Financial Results

Zosano Pharma Reports Second Quarter 2021 Financial Results

FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

“We are pleased to have initiated the healthy volunteer pharmacokinetic study that was requested by the FDA for the resubmission of the New Drug Application (NDA) for M207,” said Steven Lo, president and chief executive officer of Zosano. “The study is evaluating pharmacokinetics and safety in approximately 48 healthy volunteers. We are diligently working to complete this study in the third quarter. Pending receipt of positive data, we plan to resubmit the NDA for M207 by year-end. Additionally, this quarter we strengthened our patent portfolio with the issuance of a U.S. patent covering method of use of M207.”

Select Business Highlights

  • Initiated the pharmacokinetic study required to support the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) NDA
  • Announced publication of an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” in The Journal of Headache and Pain highlighting the positive safety and efficacy results from this long-term study
  • Received notification of a newly issued U.S. patent for method of rapidly achieving therapeutic levels with M207 for the acute treatment of migraine
  • Appointed Kathy McGee, an accomplished biopharmaceutical executive currently serving as the chief operating officer of AVITA MEDICAL, to the board of directors

Financial Results for the Second Quarter Ended June 30, 2021

Zosano reported a net loss for the second quarter of 2021 of $6.1 million, or $0.06 per share on a basic and diluted basis, compared with a net loss of $7.9 million, or $0.14 per share on a basic and diluted basis, for the same quarter in 2020. The net loss for the second quarter of 2021 included a $1.6 million gain on the forgiveness of our Paycheck Protection Loan.

Research and development expenses for the second quarter of 2021 were $5.0 million, compared with $4.9 million for the same quarter in 2020. The increase was primarily due to an increase of $0.2 million in manufacturing costs related to the scale up and technology transfer to our commercial manufacturing organizations and $0.2 million in increased spending for clinical trials. These increases were partially offset by a decrease of $0.3 million in employee and consulting costs.

General and administrative expenses for the second quarter of 2021 were $3.0 million compared with $2.8 million for the same quarter in 2020. The increase of $0.2 million was primarily due to higher employee related costs.

As of June 30, 2021, cash and cash equivalents were $22.1 million, compared with $35.3 million as of December 31, 2020.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Previously, M207 was known as Qtrypta, which the company no longer intends to use as the proprietary name of M207. The Company is currently in the process of identifying an alternative proprietary name for M207. Learn more at

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s ongoing pharmacokinetic study and the anticipated timing with respect to the study; the expected timing of the potential resubmission of the NDA for M207, the potential benefits and availability of M207 for patients, the expectations for identifying a proprietary name for M207 and other future events and expectations described in this press release. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “scheduled,” “goal,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company’s ability to obtain additional cash resources to continue operations, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contacts:

Christine Matthews

Chief Financial Officer

510-745-1200

Zosano PR:

Sylvia Wheeler or Alexandra Santos

 or 





ZOSANO PHARMA CORPORATION

BALANCE SHEETS

(in thousands, except par value and share amounts)

 June 30,

2021
 December 31,

2020
 (unaudited)  
ASSETS
Current assets:   
Cash and cash equivalents$22,058  $35,263 
Prepaid expenses and other current assets1,787  453 
Total current assets23,845  35,716 
Restricted cash455  455 
Property and equipment, net32,184  30,909 
Operating lease right-of-use assets4,366  4,928 
Other long-term assets  3 
Total assets$60,850  $72,011 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:   
Accounts payable$1,677  $1,884 
Accrued compensation1,801  2,294 
Build-to-suit obligation, current portion, net of debt issuance costs and discount4,825  4,779 
Operating lease liabilities, current portion1,492  1,378 
Paycheck Protection Program loan, current portion  809 
Other accrued liabilities1,620  3,367 
Total current liabilities11,415  14,511 
Build-to-suit obligation, long-term portion, net of debt issuance costs and discount2,237  4,359 
Operating lease liabilities, long-term portion3,911  4,687 
Paycheck Protection Program loan, long-term portion  812 
Other long-term liabilities221  127 
Total liabilities17,784  24,496 
    
Stockholders’ equity:   
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2021 and December 31, 2020, respectively   
Common stock, $0.0001 par value; 250,000,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 113,329,291 and 102,066,218 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively11  10 
Additional paid-in capital389,531  379,695 
Accumulated deficit(346,476) (332,190)
Total stockholders’ equity43,066  47,515 
Total liabilities and stockholders’ equity$60,850  $72,011 





ZOSANO PHARMA CORPORATION

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts)

(unaudited)

 Three Months Ended June 30, Six Months Ended June 30,
 2021 2020 2021 2020
        
Service revenue$188  $  $446  $ 
Operating expenses:       
Cost of service revenue202    364   
Research and development5,000  4,932  10,330  10,446 
General and administrative2,958  2,766  5,772  5,848 
Total operating expenses8,160  7,698  16,466  16,294 
Loss from operations(7,972) (7,698) (16,020) (16,294)
Other income (expense):       
Interest income  5  1  15 
Interest expense(22) (190) (119) (396)
Other income (expense), net1,850  (12) 1,852  91 
Loss before provision for income taxes(6,144) (7,895) (14,286) (16,584)
Provision for income taxes       
Net loss and comprehensive loss$(6,144) $(7,895) $(14,286) $(16,584)
        
Net loss per common share – basic and diluted$(0.06) $(0.14) $(0.13) $(0.36)
Weighted-average common shares used in computing net loss per common share – basic and diluted108,943  54,927  106,662  45,597 



EN
10/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zosano Pharma Corp

 PRESS RELEASE

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a “debtor-in-poss...

 PRESS RELEASE

Zosano Pharma Reports First Quarter 2022 Financial Results

Zosano Pharma Reports First Quarter 2022 Financial Results FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared wit...

 PRESS RELEASE

Zosano Pharma Provides Corporate Update

Zosano Pharma Provides Corporate Update FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its M207 New Drug Application. However, in order to preserve its capital and cash resources, Zosano has suspended its M207 program. Additionally, the company’s remaining feasibility study with a pharmaceutical partner is expected to conclude this quarter. Zos...

 PRESS RELEASE

Zosano Pharma Announces Reverse Stock Split Effective Today

Zosano Pharma Announces Reverse Stock Split Effective Today ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022 FREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock. The reverse stock split will become effective today, April 11, 2022. The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on April 12, 202...

 PRESS RELEASE

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Re...

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. “We are in discussions with the FDA to determine if there is a viable option to pursue approval of M207 using the currently available clinical data. In addition, we are actively evaluating financial and strategic alternatives in collaboration with external advi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch